Previous Close | 2.45 |
Open | 2.40 |
Bid | 2.35 x 1000 |
Ask | 2.40 x 1000 |
Day's Range | 2.35 - 2.40 |
52 Week Range | 1.55 - 5.75 |
Volume | 219,069 |
Avg. Volume | 448,538 |
Market Cap | 119.613M |
Beta | 1.54 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.10 |
Earnings Date | Oct 30, 2017 - Nov 3, 2017 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 4.42 |
LONDON, UK / ACCESSWIRE / April 18, 2018 / Active-Investors.com has just released a free research report on AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) ("AcelRx").If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ACRX as the Company's latest news hit the wire. On April 16, 2018, the specialty pharmaceutical Company, which is focused on the development and commercialization of innovative therapies for the treatment of acute pain, declared the successful completion of the human factor study to validate the effectiveness of the revised DSUVIA directions for use (DFU).
REDWOOD CITY, Calif. , April 18, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies ...
REDWOOD CITY, Calif. , April 16, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx or the Company), a specialty pharmaceutical company focused on innovative therapies for use in ...
REDWOOD CITY, Calif., April 11, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported the publication of a report commissioned by AcelRx analyzing the economic burden associated with administration of intravenous (IV) morphine for acute pain in the emergency department (ED) in the peer-reviewed journal Drugs in Context. This manuscript reports on the results of a micro-costing analysis to estimate the burden of IV administration of morphine in five key European countries based on a literature review.
REDWOOD CITY, Calif. , March 27, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx" or the "Company"), a specialty pharmaceutical company focused on innovative ...
Stock Monitor: AcelRx Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 26, 2018 / Active-Investors.com has just released a free research report on Orthofix International N.V. (NASDAQ: OFIX ...
AcelRx Pharmaceuticals Inc’s (NASDAQ:ACRX): AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. The US$101.80M market-cap company announcedRead More...
Q4 2017 AcelRx Pharmaceuticals Inc Earnings Call
NEW YORK, NY / ACCESSWIRE / March 9, 2018 / Biotech stocks AcelRx and TherapeuticsMD both saw gains on Thursday with the gains extended into after-hours trading. AcelRx moved higher despite reporting a ...
The Redwood City, California-based company said it had a loss of 20 cents per share. The drugmaker posted revenue of $740,000 in the period. For the year, the company reported that its loss widened to ...
- FDA Type A meeting in January 2018 provides path to DSUVIA™ NDA resubmission expected in Q2 2018 - $60.5 million of cash and short-term investments at December 31, 2017 - Q4 2017 combined G&A and R&D ...
REDWOOD CITY, Calif. , March 8, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx or the Company), a specialty pharmaceutical company focused on innovative therapies for use in ...
NEW YORK, NY / ACCESSWIRE / March 8, 2018 / AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 8, 2018 at 4:30 PM Eastern ...
Surging implied volatility makes AcelRx Pharmaceuticals (ACRX) lucrative to the option traders.
REDWOOD CITY, Calif. , March 5, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative ...
REDWOOD CITY, Calif. , March 2, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release fourth quarter and yearly financial ...
NEW YORK, Feb. 20, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Pinnacle ...
REDWOOD CITY, Calif. , Feb. 16, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative ...
Omeros (OMER) inks an agreement with the FDA on Omeros' protocol for a phase III study to evaluate its lead pipeline candidate, OMS721, for treatment of patients with IgA nephropathy.
Merck's (MRK) anti-PD-1 therapy, Keytruda, gains approval in Japan for previously-treated patients with bladder cancer. Keytruda can now be indicated for four types of cancer in Japan.
Examining AcelRx Pharmaceuticals Inc’s (NASDAQ:ACRX) past track record of performance is an insightful exercise for investors. It allows us to reflect on whether or not the company has met orRead More...
Other than a bullish rank, there are several factors that make Emergent (EBS) a solid investment in 2018.
Independent Data Monitoring Committee endorses evaluation of Actinium's (ATNM) lead pipeline candidate, Iomab-B, for a pivotal phase III SIERRA study.
Stock Monitor: AcelRx Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / December 08, 2017 / Active-Investors free earnings report on Masimo Corp. (NASDAQ: MASI ) has freshly been issued to its members, ...